Tazemetostat (Tazverik®)Management in Relapsed/Refractory Follicular Lymphoma

The continuous change and evolution of treating and managing oncology patients has led to a significant need to promote higher quality patient care. This need motivated NCODA to develop the Positive Quality Intervention (PQI) as a peer-reviewed clinical guidance resource for healthcare providers. By providing Quality Standards and effective practices around a specific aspect of cancer care, PQIs equip the entire multidisciplinary care team with a sophisticated yet concise resource for managing patients receiving oral or IV oncolytics. This PQI in Action is a follow up to the Tazemetostat (TAZVERIK®) Management in Relapsed/Refractory Follicular Lymphoma PQI and explores how the medically integrated teams at Utah Cancer Specialists (UCS) and Tennessee Cancer Specialists incorporate PQIs as part of their daily workflow. This article will discuss how utilizing the Tazemetostat (TAZVERIK®) Management in Relapsed/Refractory Follicular Lymphoma PQI elevates patient care.